1. 2020
  2. Targeting the tyrosine kinase inhibitor-resistant mutant EGFR pathway in lung cancer without targeting EGFR?

    De Greve, J. & Giron, P., Feb 2020, In : Translational Lung Cancer Research. 9, 1, p. 1-3 3 p.

    Research output: Contribution to journalEditorial

  3. 18F-FDG PET/CT based spleen to liver ratio associates with clinical outcome to ipilimumab in patients with metastatic melanoma

    Wong, A., Callahan, J., Keyaerts, M., Neyns, B., Mangana, J., Aberle, S., Herschtal, A., Fullerton, S., Milne, D., Iravani, A., McArthur, G. A. & Hicks, R. J., 2020, In : Cancer imaging. 20, 1, 36.

    Research output: Contribution to journalArticle

  4. 2019
  5. Worsening and newly diagnosed paraneoplastic syndromes following anti-PD-1 or anti-PD-L1 immunotherapies, a descriptive study

    Manson, G., Maria, A. T. J., Poizeau, F., Danlos, F-X., Kostine, M., Brosseau, S., Aspeslagh, S., Du Rusquec, P., Roger, M., Pallix-Guyot, M., Ruivard, M., Dousset, L., Grignou, L., Psimaras, D., Pluvy, J., Quéré, G., Grados, F., Duval, F., Bourdain, F., Maigne, G. & 12 others, Perrin, J., Godbert, B., Taifas, B. I., Forestier, A., Voisin, A-L., Martin-Romano, P., Baldini, C., Marabelle, A., Massard, C., Honnorat, J., Lambotte, O. & Michot, J-M., 3 Dec 2019, In : Journal for immunotherapy of cancer. 7, 1, 337.

    Research output: Contribution to journalArticle

Previous 1 2 3 4 5 6 7 8 ...57 Next

ID: 25692